Human-based formulation IMOVAX® Rabies is grown in MRC-5 human diploid-cell line and contains phenol, betapropiolactone, and neomycin no known specific contraindications for postexposure treatment Safe and well tolerated Only supplier of both pre- and postexposure rabies product Round-the-clock telephone contact Special delivery available for emergency rooms Safety Information IMOVAX® Rabies Adverse reactions due to administration of the rabies vaccine may include pain, redness, swelling, and itching at the injection site; headache, nausea, abdominal pain, muscle aches, and dizziness are also possible. For postexposure treatment, there are no known specific contraindications. For pre-exposure immunization, the only known contraindication is the development of febrile illness, etc. IMOGAM® Rabies–HT Adverse reactions due to administration of rabies immune globulin may include tenderness, pain, soreness, and muscle stiffness at the injection site. Administration of IMOGAM® Pre-exposure immunization1...   Vaccination Schedule Treatment Needed   Day 0 IMOVAX® Rabies   Day 7 IMOVAX® Rabies   Day 21 or 28 IMOVAX® Rabies …and postexposure treatment1 Postexposure treatment for those who have received pre-exposure vaccinations3   Vaccination Schedule Treatment Needed   Day 0 IMOVAX® Rabies   Day 3 IMOVAX® Rabies   Postexposure treatment for those who have not received pre-exposure immunization   Vaccination Schedule Treatment Needed   Day 0 IMOVAX® Rabies IMOGAM® Rabies–HT   Day 3 IMOVAX® Rabies   Day 7 IMOVAX® Rabies   Day 14 IMOVAX® Rabies   Day 28 IMOVAX® Rabies Rabies–HT in repeated doses once vaccine treatment has been initiated is contraindicated. As with any vaccine, vaccination with a rabies vaccine or rabies immune globulin may not protect 100% of susceptible individuals. Click to view full Prescribing Information for IMOGAM® Rabies–HT and IMOVAX® Rabies. IMOGAM® Rabies–HT and IMOVAX® Rabies are manufactured by Aventis Pasteur SA and distributed by Aventis Pasteur Inc. References: 1. Centers for Disease and Prevention (CDC). Human Rabies prevention—United States, 1999: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Mortal Weekly Rep. 1999;48 (RR-1):1-21. 2. IMOVAX® Rabies, Rabies Vaccine, Prescribing Information, July 1991.